U-77891 Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

U-77891 is an opioid analgesic drug that was first synthesized in 1983 by the Upjohn company.[1] It was originally synthesized to prove that the removal of a single methylene spacer of the benzamide would alter a κ-opioid receptor agonist such as U-50488 into an μ-opioid receptor agonist, as well as producing a semi-rigid derivative of U-47700. This would help elucidate the relative positions of the hydrogen-bond acceptors and substituted aromatic system to find the compound with the lowest Ki value in a series of benzamide opioids dating back to the 1970s.[2] The original work found a mixture of agonists and antagonists.
wikipedia

Verwenden

trans-3,4-Dibromo-N-methyl-N-(1-methyl-1-azaspiro[4.5]dec-6-yl)-benzamide is a μ-opioid, δ-opioid and κ-opioid receptors agonist and an analgesic agent.

U-77891 Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

U-77891 Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
Dorne Chemical Technology co. LTD	+86-86-13583358881 +8618560316533	Ethan@dornechem.com	China	3095	58

---

• Benzamide, 3,4-dibromo-N-methyl-N-[(5R,6S)-1-methyl-1-azaspiro[4.5]dec-6-yl]-, rel-
• trans-3,4-Dibromo-N-methyl-N-(1-methyl-1-azaspiro[4.5]dec-6-yl)-benzamide
• U-77891
• 119878-31-8
• C18H24Br2N2O